

O &amp; P E

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FEB 20 2004

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	09/875,076
Filing Date	June 6, 2001
First Named Inventor	Ruoping Chen
Art Unit	1646
Examiner Name	Prema Mertz
Attorney Docket Number	11.US9.DIV

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
PM	AA	US-2003/0125539 A1	07/03/2003	Bonini et al	
	AB	US- 2003/0064381	04/03/2003	Bonini et al	
	AC	US- 6,468,756	10/22/2002	Bonini et al	
	AD	US- 6,221,660	04/24/2001	Bonini et al	
	AE	US- 5,932,445	08/03/1999		
	AF	US 2003/0180813	09/25/2003		
✓	AG	US-2003/0139590	07/24/2003		

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
PM	BA	EP 1 092 727 A2	01/18/2001	Pfizer Limited et al		
	BB	WO 01/32864 A1	02/10/2001	Merck Patent GMBH et al		
	BC	WO 01/87929 A2	11/22/2001	Bayer Aktiengesellschaft et al.		
	BD	WO 00/31258 A2	06/02/2000	Arena Pharmaceuticals Inc., et al		
	BE	WO 01/36473 A2	05/25/2001	Pharmacia & Upjohn Co.		
	BF	WO 00/50562	08/31/2000	Synaptic Corporation		
	BG	WO 01/42288 A2	06/14/2001	incyte Genomics, Inc.		
	BH	WO 02/186548 A2 (w/ English Abstract)	02/28/2002	Japan Science and Technology Corporation		
	BI	WO 02/0244362 A1 (w./ English Abstract)	06/06/2002	Yamanouchi Pharmaceutical Co., Ltd.		
	BJ	EP 1338651	08/27/2003	Yamanouchi Pharmaceutical Co. Ltd.		
	BK					
	BL					
	BM					

Examiner  
Signature

Prema Mertz


Date  
Considered

8/31/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	09/875,076
Filing Date	June 6, 2001
First Named Inventor	Ruoping Chen
Group Art Unit	1646
Examiner Name	Prema Mertz
Attorney Docket Number	11.US9.DIV

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PM	CA	Bentley, "Genomic sequence information should be release immediately and freely to the public," The Sanger Institute: Human Genome Project, Policy Forum, Science (1996) 274:533-534.	
	CB	The Sanger Institute: Data Release Policy, www.sanger.ac.uk, May 24, 2002.	
	CC	Genbank Acc. #AL035423, update version of February 12, 1999. Pearce A.	
	CD	Genbank Acc #AL035423, update version of February 24, 1999. Pearce A.	
	CE	Genbank Acc. #AL035423, update version of February 27, 1999. Pearce A.	
	CF	Genbank Acc. #AL035423, update version of April 21, 1999 Pearce A.	
	CG	Genbank Acc. #AL035423, update version of November 23, 1999. Pearce A.	
✓	CH	Sequence Revision History for Genbank Acc. #AL035423.	
	CI		
	CJ		

Examiner Signature	Prema Mertz	Date Considered	8/31/04
--------------------	-------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.